Cerebral Palsy (CP)NCT06486597
Whole Body Metabolism in Children With Cerebral Palsy With Low Skeletal Muscle Mass
A study testing Meal in people with Cerebral Palsy (CP), run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
Trial summary
At the center of pediatrics in Copenhagen the investigators experience that the children with CP with low skeletal muscle mass have more complications and admission after for example surgery is prolonged due to these complications. Read more about this study
- Who is it for?
- Ages 2 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Cerebral Palsy (CP)
- What is being tested?
- Meal
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Aug 2023to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- -Children with cerebral palsy with low skeletal muscle mass
- o Being wheelchair dependent GMFCS IV-V
- Healthy controls: Children admitted to the EMU because of either
- Classification of epilepsy or to rule out differential diagnoses of epilepsy
- Nocturnal EEG changes
- Age:
- o 2-18 years
- Signed informed consent to participation in the trial.
Who cannot join
- Inability to understand the purpose of the trial or cooperate in the conduction of the experiments. For the children this will concern of course the parents or the guardians of the child.
- Competing conditions at risk of compromising the results of the study.
- In healthy children, concerns that participation in the trial may affect the diagnostic quality of the EMU investigation
- Participation in other trials that may interfere with the results.
- Intake of medications that may interfere with the results, evaluated by investigator.
- Pregnancy or breastfeeding.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Department of Pediatrics and Adolescent Medicine and Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, Copenhagen Ø, 2100
Mette Cathrine Ørngreen, MD, DMSc, 35455935, mette.cathrine.oerngreen.01@regionh.dk
Mette Cathrine Ørngreen, MD, DMSc
About this study
At the center of pediatrics in Copenhagen the investigators experience that the children with CP with low skeletal muscle mass have more complications and admission after for example surgery is prolonged due to these complications. In order to prevent malnutrition and energy insufficiency as well as obesity and cardiometabolic disorders in adulthood, and with the aim of defining biomarkers for energy needs, the investigators wish to determine energy and protein needs in children with CP.
The investigators wish to investigate the whole-body metabolism in children with cerebral palsy (CP) and compare the results with results from healthy children. The investigators aim to include 10 children (aged 2-18 years) with CP with low skeletal muscle mass and 10 healthy controls (aged 2-18 years). By using stable isotope technique the investigators will investigate systemic fat, glucose and protein metabolism together with liver protein degradation and glucose production. Furthermore, by using DXA scan the investigators will describe the quality and distribution of skeletal muscle. Lastly, the investigators will determine the skeletal muscle signal pathway and metabolism in skeletal muscle via the Bergström biopsy technique in vastus lateralis.
Read the detailed description
Trial design and time frame:
A prospective, non-randomized, cross-sectional study.
There will be two different groups included:
- Children with cerebral palsy with low skeletal muscle mass
- Healthy controls: Children admitted to the hospital at the Epilepsy monitor unit (EMU for conditions not affecting metabolic function)
The trial will be conducted over a total of five days and takes place at the Copenhagen Neuromuscular Centre, Department of Neurology or Department of Pediatrics and Adolescent Medicine, Rigshospitalet
Study Day 1: The patient will be DXA-scanned or fat mass will be measured by a fat caliper, and the patient will complete quality of life questionnaire and pain scores.
Study Day 2 (Study type A): The stable isotope infusion will take place. The subjects will arrive around 08.00, at Copenhagen Neuromuscular Centre (CNMC), Rigshospitalet or Department of Pediatrics and Adolescents medicine, Rigshospitalet. Otherwise, the study will take place when the child is admitted for change of baclofen pump or minor surgery, where they typically will be hospitalized for 1-3 days at Rigshospitalet or Skejby hospital at the Department of Pediatrics and Adolescents or the Orthopedic Departments.
On arrival, EMLA (local anesthetics cream) will be applied on the skin of the children to minimize any discomfort that may occur during IV-insertion. Two peripheral venous catheters are inserted, one in the medial cubital vein for infusion of stable isotopes, and one in a dorsal vein of the hand for blood sampling. Most of the children already have a permanent catheter, and in this case the permanent catheter will be used for infusion of stable isotopes.
Background samples will be collected before the start of tracer infusion. After 1 hour and 45 minutes of basal tracer infusion, basal blood samples are drawn (time -15 and -30) for the determination of basal steady state tracer enrichments and hormone concentrations. At time= 0, a liquid mixed meal is provided. Blood samples are drawn regularly for 6 hours and more frequently the first hour after the test meal ingestion (at 0, 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300 and 360 minutes). If the child becomes upset or the investigators for other reasons want to stop earlier than 6 hours, the already obtained blood and urine samples will be analyzed and included in the results.
Study days 3, 4, and 5 (Study type B and C):
These study days are optional to the families and the investigator. For some families one study day is what they can fit into their calendar, and the investigators want to respect that, for those who accept to continue the study for more than one day, the following days are included.
The doubly labeled water technique measures energy consumption over a prolonged period, in our study for 1 week. A drink with doubly labeled water will be ingested, and energy expenditure is measured by urine and blood sampling. This method is repeated at 3 hours and 4 hours after the drink intake and again at day 3 and day 7. Furthermore, a drink with 13C will be ingested, and breath tests collected in vacutainers with straws will be collected for analysis of energy expenditure. Measuring energy expenditure with these two less non-invasive methods and comparing results with the detailed meal test, will pave the way for developing simple diagnostic markers for metabolism in the children.
The tracers: In this study, the investigators will intravenously infuse small amounts of metabolites labelled with stable isotopes in primed continuous intravenous infusions of: D8-Phenylalanine, D2-Tyrosine, 13C18-Oleate acid, D2-Glucose, D5-Glycerol. This method is well-established at both CIMT and CNMC and has been used investigating several of patients categories before: Neonates (ongoing study), gastric sleeve, elderly and neuromuscular patients.
The tracers are prepared from the hospital pharmacy. All tracers are purchased from Cambridge Isotope Laboratories, Andover, MA, USA suitable for human use. Stable isotopes are non-radioactive and naturally occurring in food (e.g. in corn).
Food intervention: At time= 0 (120 minutes after infusion), a liquid mixed meal adjusted by weight is given. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Intrinsically labeled caseinate was produced via an infusion of [D5]-phenylalanine and [D3]leucine into a lactating cow to obtain enriched milk Foulumn, Arhus University, from which the caseinate fraction was isolated at Arla Foods according to Good Manufacturing Practice (GMP) and safety checked an store under appropriate regulatory conditions until use (Nørre Vium, Denmark) following a previously described procedure.
Analyses of blood samples:The samples will be collected in syringes containing 10μL EDTA/mL to prevent coagulation. The blood is immediately centrifuged at 4oC to separate plasma from red blood cells. The samples will be frozen in coded tubes and stored at -80C until analysis.
Routine blood samples: Will be analysed immediately at the Department of Clinical Biochemistry, Rigshospitalet:
- Blood samples include: Insulin, HbA1C, Cholesterol, HDL, LDL, triglycerides
Glucose and lactate: will be analyzed (ABL 700) immediately as the blood is drawn.
Specific blood samples:
Free fatty acids: will be analyzed using fluorometry. Hormones (catecholamines, insulin, incretins and glucagon): will be analyzed using RIA and Elisa Methods respectively. Stable isotope enrichments in blood: will be analyzed using Liquid chromatography-tandem mass-spectrometry (LC-MS/MS) and gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS) (Thermo Scientific, Palo Alto, CA, USA and Bremen, Germany). Calculations: Whole body metabolite quantitative kinetics will be calculated using Steele's equation for non-steady state adapted for analysis of stable isotopes under the post-absorptive conditions.
- Conditions
- Cerebral Palsy (CP)
- Being tested
- Meal
- Medical subject headings
- Cerebral Palsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MealDietary supplement
Liquid meal
| Study group | Role | What they receive |
|---|---|---|
| Meal intervention with stable isotopes | Experimental | A liquid mixed meal are gived adjusted by weight. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Blood samples are drawn frequently to measure fat, glucose and protein metabolism. Receives: Dietary Supplement: Meal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Protein breakdown
Phenylalanine Rate of appearance micro mol/kgFFM/min in a fasted and fed state
Measured: 10 hours
Secondary outcomes (11)
Muscle biopsy
Muscle morphology
Measured: 10 hours
Life quality score
Life quality score by using Pediatric Quality of Life Inventory (PedsQL) (0-100), high score indicates worse qualiity of life.
Measured: 10 hpurs
Quality of Skeletal Muscle
Dual-energy X-ray absorptiometry (DEXA) scan
Measured: 10 hours
Metabolities
Concentration of plasma amino acids (mmol/L), concentration of glucose (mmol/L), concentration of palmitate (micromol/L), concentration of free fatty acids (mmol/L) and levels of HbA1c (mmol/mol)
Measured: 10 hours
Hormones
Concentration of Insulin (pmol/L), concentration of catecholamines (nmol/l) , glucagon (pmol/L), gut hormones and incretins (GLP-1 (pmol/L) and GIP, (pmol/L))
Measured: 10 hours
Energy utilization
Energy expenditure assessed by doubly labeled water method and 13C breath test to test that these methods are valuable and can be used in the future as less expensive and invasive methods to measure energy utilization.
Measured: 10 hours
Muscle biopsy
muscle fiber type
Measured: 10 hours
muscle biopsy
size
Measured: 10 hours
Muscle biopsy
Protein markers: MuRF1, MAFbx, FoxO (ng/mg total protein)
Measured: 10 hours
Muscle biopsy
muscle generating markers: Myo D, Myogenin, IGF1 (ng/mg total protein )
Measured: 10 hours
Muscle biopsy
Muscle growth regulating protein (myostatin)
Measured: 10 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2024
- Study start1 Aug 2023
- Primary completion31 Jul 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral Palsy (CP)Studies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mette Cathrine Oerngreen, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06486597
- Sponsor's protocol ID
- 22-B01-1066
- Status last verified
- Feb 2025
- First submitted
- 17 May 2024
- Last updated
- 26 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Whole Body Metabolism in Children With Cerebral Palsy With Low Skeletal Muscle Mass
- ClinicalTrials.gov ID
- NCT06486597
- Acronym / sponsor ID
- 22-B01-1066
- Conditions
- Cerebral Palsy (CP)
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 31 Jul 2028 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 3 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
At the center of pediatrics in Copenhagen the investigators experience that the children with CP with low skeletal muscle mass have more complications and admission after for example surgery is prolonged due to these complications. In order to prevent malnutrition and energy insufficiency as well as obesity and cardiometabolic disorders in adulthood, and with the aim of defining biomarkers for energy needs, the investigators wish to determine energy and protein needs in children with CP.
The investigators wish to investigate the whole-body metabolism in children with cerebral palsy (CP) and compare the results with results from healthy children. The investigators aim to include 10 children (aged 2-18 years) with CP with low skeletal muscle mass and 10 healthy controls (aged 2-18 years). By using stable isotope technique the investigators will investigate systemic fat, glucose and protein metabolism together with liver protein degradation and glucose production. Furthermore, by using DXA scan the investigators will describe the quality and distribution of skeletal muscle. Lastly, the investigators will determine the skeletal muscle signal pathway and metabolism in skeletal muscle via the Bergström biopsy technique in vastus lateralis.
Detailed description
Trial design and time frame:
A prospective, non-randomized, cross-sectional study.
There will be two different groups included:
- Children with cerebral palsy with low skeletal muscle mass
- Healthy controls: Children admitted to the hospital at the Epilepsy monitor unit (EMU for conditions not affecting metabolic function)
The trial will be conducted over a total of five days and takes place at the Copenhagen Neuromuscular Centre, Department of Neurology or Department of Pediatrics and Adolescent Medicine, Rigshospitalet
Study Day 1: The patient will be DXA-scanned or fat mass will be measured by a fat caliper, and the patient will complete quality of life questionnaire and pain scores.
Study Day 2 (Study type A): The stable isotope infusion will take place. The subjects will arrive around 08.00, at Copenhagen Neuromuscular Centre (CNMC), Rigshospitalet or Department of Pediatrics and Adolescents medicine, Rigshospitalet. Otherwise, the study will take place when the child is admitted for change of baclofen pump or minor surgery, where they typically will be hospitalized for 1-3 days at Rigshospitalet or Skejby hospital at the Department of Pediatrics and Adolescents or the Orthopedic Departments.
On arrival, EMLA (local anesthetics cream) will be applied on the skin of the children to minimize any discomfort that may occur during IV-insertion. Two peripheral venous catheters are inserted, one in the medial cubital vein for infusion of stable isotopes, and one in a dorsal vein of the hand for blood sampling. Most of the children already have a permanent catheter, and in this case the permanent catheter will be used for infusion of stable isotopes.
Background samples will be collected before the start of tracer infusion. After 1 hour and 45 minutes of basal tracer infusion, basal blood samples are drawn (time -15 and -30) for the determination of basal steady state tracer enrichments and hormone concentrations. At time= 0, a liquid mixed meal is provided. Blood samples are drawn regularly for 6 hours and more frequently the first hour after the test meal ingestion (at 0, 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300 and 360 minutes). If the child becomes upset or the investigators for other reasons want to stop earlier than 6 hours, the already obtained blood and urine samples will be analyzed and included in the results.
Study days 3, 4, and 5 (Study type B and C):
These study days are optional to the families and the investigator. For some families one study day is what they can fit into their calendar, and the investigators want to respect that, for those who accept to continue the study for more than one day, the following days are included.
The doubly labeled water technique measures energy consumption over a prolonged period, in our study for 1 week. A drink with doubly labeled water will be ingested, and energy expenditure is measured by urine and blood sampling. This method is repeated at 3 hours and 4 hours after the drink intake and again at day 3 and day 7. Furthermore, a drink with 13C will be ingested, and breath tests collected in vacutainers with straws will be collected for analysis of energy expenditure. Measuring energy expenditure with these two less non-invasive methods and comparing results with the detailed meal test, will pave the way for developing simple diagnostic markers for metabolism in the children.
The tracers: In this study, the investigators will intravenously infuse small amounts of metabolites labelled with stable isotopes in primed continuous intravenous infusions of: D8-Phenylalanine, D2-Tyrosine, 13C18-Oleate acid, D2-Glucose, D5-Glycerol. This method is well-established at both CIMT and CNMC and has been used investigating several of patients categories before: Neonates (ongoing study), gastric sleeve, elderly and neuromuscular patients.
The tracers are prepared from the hospital pharmacy. All tracers are purchased from Cambridge Isotope Laboratories, Andover, MA, USA suitable for human use. Stable isotopes are non-radioactive and naturally occurring in food (e.g. in corn).
Food intervention: At time= 0 (120 minutes after infusion), a liquid mixed meal adjusted by weight is given. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Intrinsically labeled caseinate was produced via an infusion of [D5]-phenylalanine and [D3]leucine into a lactating cow to obtain enriched milk Foulumn, Arhus University, from which the caseinate fraction was isolated at Arla Foods according to Good Manufacturing Practice (GMP) and safety checked an store under appropriate regulatory conditions until use (Nørre Vium, Denmark) following a previously described procedure.
Analyses of blood samples:The samples will be collected in syringes containing 10μL EDTA/mL to prevent coagulation. The blood is immediately centrifuged at 4oC to separate plasma from red blood cells. The samples will be frozen in coded tubes and stored at -80C until analysis.
Routine blood samples: Will be analysed immediately at the Department of Clinical Biochemistry, Rigshospitalet:
- Blood samples include: Insulin, HbA1C, Cholesterol, HDL, LDL, triglycerides
Glucose and lactate: will be analyzed (ABL 700) immediately as the blood is drawn.
Specific blood samples:
Free fatty acids: will be analyzed using fluorometry. Hormones (catecholamines, insulin, incretins and glucagon): will be analyzed using RIA and Elisa Methods respectively. Stable isotope enrichments in blood: will be analyzed using Liquid chromatography-tandem mass-spectrometry (LC-MS/MS) and gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS) (Thermo Scientific, Palo Alto, CA, USA and Bremen, Germany). Calculations: Whole body metabolite quantitative kinetics will be calculated using Steele's equation for non-steady state adapted for analysis of stable isotopes under the post-absorptive conditions.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Meal intervention with stable isotopes | Experimental | Dietary Supplement: MealA liquid mixed meal are gived adjusted by weight. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Blood samples are drawn frequently to measure fat, glucose and protein metabolism. |
Who may qualify
- Ages
- 2 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (8 listed)
- -Children with cerebral palsy with low skeletal muscle mass
- o Being wheelchair dependent GMFCS IV-V
- Healthy controls: Children admitted to the EMU because of either
- o 2-18 years
- Signed informed consent to participation in the trial.
Key exclusion criteria (6 listed)
- Inability to understand the purpose of the trial or cooperate in the conduction of the experiments. For the children this will concern of course the parents or the guardians of the child.
- Competing conditions at risk of compromising the results of the study.
- In healthy children, concerns that participation in the trial may affect the diagnostic quality of the EMU investigation
- Participation in other trials that may interfere with the results.
- Intake of medications that may interfere with the results, evaluated by investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MealLiquid meal | Dietary supplement | Meal intervention with stable isotopes |
Primary outcome
Protein breakdown
Time frame: 10 hours
Phenylalanine Rate of appearance micro mol/kgFFM/min in a fasted and fed state
11 secondary outcomes
Muscle biopsy
Time frame: 10 hours
Life quality score
Time frame: 10 hpurs
Quality of Skeletal Muscle
Time frame: 10 hours
Metabolities
Time frame: 10 hours
Hormones
Time frame: 10 hours
Energy utilization
Time frame: 10 hours
Muscle biopsy
Time frame: 10 hours
muscle biopsy
Time frame: 10 hours
Muscle biopsy
Time frame: 10 hours
Muscle biopsy
Time frame: 10 hours
Muscle biopsy
Time frame: 10 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Feb 2025.
Related trials for Cerebral Palsy (CP)
Recruiting
Additional Effects on tDCS With AOT on Lower Limb Functions on Children With Diplegic CP
Diplegic Cerebral Palsy
Recruiting
Comparison of Vestibular Stimulation and Core Stability Training on Sitting Balance in Hypotonic CP
Hypotonic Cerebral Palsy
Not yet recruiting
Video-based Visual Feedback Combined With Task-oriented Physiotherapy Among Cerebral Palsy
Cerebral Palsy (CP)
RecruitingObservational study
Turkish Translation, Cross-Cultural Adaptation, Validity, and Reliability of the ABILHAND-Kids Young CP Scale
Cerebral Palsy
Active, not recruiting
Local Vibration for Drooling in Children With Cerebral Palsy
Cerebral Palsy (CP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Department of Pediatrics and Adolescent Medicine and Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, Denmark
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Meal in people with Cerebral Palsy (CP), run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Protein breakdown (time frame: 10 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2025.